Redeye makes slight forecast adjustments following Hoylu’s Q3 2022 report.
Redeye thinks that the Q3 report was in line with its estimates but that more is needed to turn the ...
While Q3 was still burdened by high costs, we note the market environment looks to be starting to im...
Q3 net sales and operating profit from Scanfil were close to consensus (Refinitiv) and the company e...
Redeye retains its positive view of Fortnox despite somewhat lowering its short-term forecasts and r...
Vitolife's Q3 is mixed bag with a softer Europe and a negative product mix resulting in 5% organic ...
Fortsatt stark efterfrågan… Lagercrantz växte försäljningen 11% organiskt och är därmed på rekordhög...
Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in o...
Tillväxten avtar i Q3 Bubblerooms omsättning för Q3 växte 2% i jämförbara enheter till 91,5 mkr.
Redeye comments on SenzaGen’s Q3 sales update with total sales of SEK9m.
Redeye is positive as regards the results from a new study, further showing statistically significan...
Sales +5% vs. ABGSCe, EBIT +25% vs. ABGSCe Organic growth of 2% in line with ABGSCe 2% We expect con...
Volume decline and continued high input costs in Q3 EBIT lowered 3% for ’22e-’23e, ’24e mostly uncha...
Redeye comments on the most important events in the quarter and updates its estimates for Q3.
Q3 report softer than anticipated We decrease our ’23e-‘24e EBITA ests.
Suominen’s Q3 profitability improved a bit from the recent lows but remained very modest and below o...
The end demand has remained good for Scanfil’s services.
Innofactor showed promising progress in Q3, boding well for 2023, and now needs to provide further s...
Dovre’s Q3 results were clearly above our estimates as all three segments recorded figures higher th...
Scanfil Q3 results landed largely in line with expectations as top line was up 26% y/y and EBIT marg...
